Rasna Therapeutics focusses on development therapeutics to address the high unmet need that exists for AML and other forms of leukemia. The company's primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. Rasna Therapeutics' clinical program is based on three druggable intervention points with a potential to improve safety and efficacy of current AML combination therapies.